Ancient Bacteria Resists Modern Antibiotics
Analysis based on 12 articles · First reported Feb 17, 2026 · Last updated Feb 17, 2026
The discovery of Psychrobacter SC65A.3, resistant to modern antibiotics yet capable of inhibiting superbugs, presents a dual market impact. It highlights the growing threat of antibiotic resistance, potentially increasing demand for new antimicrobial research and development in the biotechnology and pharmaceutical sectors. Simultaneously, the unique enzymes and antimicrobial compounds from Psychrobacter SC65A.3 offer promising avenues for new drug discovery and biotechnological innovations, potentially leading to significant investment and growth opportunities for companies involved in these fields.
Researchers from the Institute of Biology Bucharest in Romania discovered a 5,000-year-old bacterial strain, Psychrobacter SC65A.3, in the Scarisoara Ice Cave. This strain exhibits resistance to 10 modern antibiotics, including rifampicin, vancomycin, and ciprofloxacin, and carries over 100 resistance-related genes. Despite its ancient origin, Psychrobacter SC65A.3 can also inhibit the growth of several major antibiotic-resistant 'superbugs' and possesses important enzymatic activities with biotechnological potential. The team, led by Cristina Purcarea, drilled a 25-meter ice core to isolate and sequence the bacterial genome, revealing almost 600 genes with unknown functions and 11 genes capable of killing other microbes. This discovery, published in Frontiers Media, offers insights into the natural evolution of antibiotic resistance and presents both a threat, if released by melting ice, and a promise for developing new antibiotics and biotechnological innovations to combat the global challenge of antimicrobial resistance.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard